Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: Rationale and design of a randomized controlled effectiveness trial

Contemporary Clinical Trials

Volumn 41, Issue , 2015, Pages 110-117

  Lee, Joshua D ^a   Friedmann, Peter D ^b   Boney, Tamara Y ^c   Hoskinson, Randall A ^b   McDonald, Ryan ^a   Gordon, Michael ^d   Fishman, Marc ^d,e   Chen, Donna T ^f   Bonnie, Richard J ^g   Kinlock, Timothy W ^d,h   Nunes, Edward V ⁱ   Cornish, James W ^c   O'Brien, Charles P ^c  

^a NEW YORK UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d FRIENDS RESEARCH INSTITUTE   (United States)

^e Maryland Treatment Centers   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g UNIVERSITY OF VIRGINIA SCHOOL OF LAW   (United States)

^h UNIVERSITY OF BALTIMORE   (United States)

ⁱ NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Criminal justice; Extended release naltrexone; Naltrexone; Opioid relapse prevention

Indexed keywords

NALTREXONE; DELAYED RELEASE FORMULATION; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CRIMINAL JUSTICE; DRUG EFFICACY; DRUG RELEASE; FOLLOW UP; GROUP THERAPY; HUMAN; MAJOR CLINICAL STUDY; OPIATE ADDICTION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SELF REPORT; TREATMENT DURATION; URINALYSIS; CRIMINAL LAW; DELAYED RELEASE FORMULATION; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; OFFENDER; OPIOID-RELATED DISORDERS; SECONDARY PREVENTION;

ADULT; CRIMINAL LAW; CRIMINALS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; SECONDARY PREVENTION;

EID: 84921901651     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2015.01.005     Document Type: Article

References (42)

1. Office of National Drug Control Policy 2013 Annual Report, Arrestee Drug Abuse Monitoring Program II 2014, Executive Office of the President, Washington, DC.
2. Lee J.D., Rich J.D. Opioid pharmacotherapy in criminal justice settings: now is the time. Subst Abus 2012, 33(1):1-4.
3. Nunn A., Zaller N., Dickman S., Trimbur C., Nijhawan A., Rich J.D. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend 2009, 105(1-2):83-88.
4. Binswanger I.A., Blatchford P.J., Mueller S.R., Stern M.F. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med 2013, 159(9):592-600.
5. Degenhardt L., Larney S., Kimber J., Gisev N., Farrell M., Dobbins T., et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction Aug 2014, 109(8):1306-1317.
6. Perry A.E., Neilson M., Martyn-St M., Glanville J., McCool R., Duffy S., et al. Pharmacological interventions for drug-using offenders. Cochrane Database Syst Rev 2013, 12:CD010862.
7. Chandler R.K., Fletcher B.W., Volkow N.D. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA 2009, 301(2):183-190. [Erratum in: JAMA 2009;301(10):1024].
8. Magura S., Lee J.D., Hershberger J., Joseph H., Marsch L., Shropshire C., et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend 2009, 99(1-3):222-230.
9. Gordon M.S., Kinlock T.W., Schwartz R.P., Couvillion K.A., Sudec L.J., O'Grady K.E., et al. Buprenorphine treatment for probationers and parolees. Subst Abus 2014, 4.
10. Gordon M.S., Kinlock T.W., Schwartz R.P., Fitzgerald T.T., O'Grady K.E., Vocci F.J. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend 2014, 142:33-40.
11. Gordon M.S., Kinlock T.W., Schwartz R.P., O'Grady K.E. A randomized clinical trial of methadone maintenance for prisoners: findings at 6months post-release. Addiction 2008, 103(8):1333-1342.
12. Friedmann P.D., Hoskinson R., Gordon M., Schwartz R., Kinlock T., Knight K., et al. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abus 2012, 33(1):9-18.
13. Awgu E., Magura S., Rosenblum A. Heroin-dependent inmates' experiences with buprenorphine or methadone maintenance. J Psychoactive Drugs 2010, 42(3):339-346.
14. Mitchell S.G., Kelly S.M., Brown B.S., Reisinger H.S., Peterson J.A., Ruhf A., et al. Incarceration and opioid withdrawal: the experiences of methadone patients and out-of-treatment heroin users. J Psychoactive Drugs 2009, 41(2):145-152.
15. Finigan M.W., Perkins T., Zold-Kilbourn P., Parks J., Stringer M. Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts. J Subst Abus Treat 2011, 41(3):288-293.
16. Comer S.D., Collins E.D., Kleber H.D., Nuwayser E.S., Kerrigan J.H., Fischman M.W. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology 2002, 159(4):351-360.
17. Bigelow G.E., Preston K.L., Schmittner J., Dong Q., Gastfriend D.R. Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course. Drug Alcohol Depend 2012, 123(1-3):57-65.
18. Comer S.D., Sullivan M.A., Yu E., Rothenberg J.L., Kleber H.D., Kampman K., et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006, 63(2):210-218.
19. Krupitsky E., Nunes E.V., Ling W., Illeperuma A., Gastfriend D.R., Silverman B.L. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011, 377(9776):1506-1513.
20. Coviello D.M., Cornish J.W., Lynch K.G., Boney T.Y., Clark C.A., Lee J.D., et al. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus 2012, 33(1):48-59.
21. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, Washington, DC.
22. Stout R.L., Wirtz P.W., Carbonari J.P., Del Boca F.K. Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol Suppl 2004, 12:70-75.
23. Veterans Administration Office of Research and Development 2015, CSP Coordinating Center, Perry Point, MD, [http://www.research.va.gov/programs/csp/perrypoint.cfm, accessed Jan. 1, 2015].
24. Lee J.D., Grossman E., DiRocco D., Truncali A., Hanley K., Stevens D., et al. Extended-release naltrexone for treatment of alcohol dependence in primary care. J Subst Abus Treat 2010, 39(1):14-21.
25. Sobell L.C., Sobell M.B. Alcohol timeline followback users' manual 1995, Addiction Research Foundation, Toronto, Canada.
26. Watkins K.E., Metzger D., Woody G., McLellan A.T. High-risk sexual behaviors of intravenous drug users in- and out-of-treatment: implications for the spread of HIV infection. Am J Drug Alcohol Abuse 1992, 18(4):389-398.
27. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., et al. The fifth edition of the Addiction Severity Index. J Subst Abus Treat 1992, 9(3):199-213.
28. Nurco D.N., Kinlock T.W., Balter M.B. The severity of preaddiction criminal behavior among urban, male narcotic addicts and two nonaddicted control groups. J Res Crime Delinq 1993, 30(3):293-316.
29. EuroQol Group EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208.
30. McLellan A.T., Alterman A.I., Cacciola J., Metzger D., O'Brien C.P. A new measure of substance abuse treatment: initial studies of the treatment services review. J Nerv Ment Dis 1992, 180(2):101-110.
31. Gardner W., Hoge S., Bennett N., Roth L., Lidz C., Monahan J., et al. Two scales for measuring patients' perceptions for coercion during mental hospital admission. Behav Sci Law 1993, 11(3):307-321.
32. Nelson R.M., Merz J.F. Voluntariness of consent for research: an empirical and conceptual review. Med Care 2002, 40(9 Suppl.):V69-V80.
33. Appelbaum P.S., Lidz C.W., Klitzman R. Voluntariness of consent to research: a conceptual model. Hastings Cent Rep 2009, 39(1):30-39.
34. Kinlock T.W., Battjes R.J., Schwartz R.P., Project Team M.T.C. A novel opioid maintenance program for prisoners: report of post-release outcomes. Am J Drug Alcohol Abuse 2005, 31(3):433-454.
35. Anton R.F., O'Malley S.S., Ciraulo D.A., Cisler R., Couper D., Donovan D., et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006, 295(17):2003-2017.
36. Kipnis K. Vulnerability in research subjects: a bioethical taxonomy. Ethical and policy issues in research involving human research participants 2001, G1-G13. National Bioethics Advisory Commission, Bethesda.
37. Pace C., Miller F., Danis M. Enrolling the uninsured in clinical trials: an ethical perspective. Crit Care Med 2003, 31(3):S121-S125.
38. London A. Undue inducements and reasonable risks: will the dismal science lead to dismal research ethics?. Am J Bioeth 2005, 5(5):29-32.
39. McGregor J. "Undue inducement" as coecive offers. Am J Bioeth 2005, 5(5):24-25.
40. Appelbaum P.S., Lidz C.W., Klitzman R. Voluntariness of consent to research: a preliminary empirical investigation. IRB 2009, 31(6):10-14.
41. Dugosh K.L., Festinger D.S., Croft J.R., Marlowe D.B. Measuring coercion to participate in research within a doubly vulnerable population: initial development of the coercion assessment scale. J Empir Res Hum Res Ethics 2010, 5(1):93-102.
42. Miller V.A., Ittenbach R.F., Harris D., Reynolds W.W., Beauchamp T.L., Luce M.F., et al. The decision making control instrument to assess voluntary consent. Med Decis Making 2011, 31(5):730-741.